Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,490
  • Shares Outstanding, K 10,242
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,630 K
  • 60-Month Beta 0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +117,629.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.42 +13.38%
on 08/15/19
1.93 -16.58%
on 09/11/19
-0.11 (-6.37%)
since 08/13/19
3-Month
1.40 +15.00%
on 08/05/19
2.15 -25.12%
on 07/16/19
-0.45 (-21.84%)
since 06/13/19
52-Week
1.11 +45.70%
on 11/15/18
9.44 -82.94%
on 01/15/19
-1.33 (-45.24%)
since 09/13/18

Most Recent Stories

More News
Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...

ADILW : 0.20 (-31.03%)
ADIL : 1.61 (unch)
Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

Application for pediatric investigation plan waiver validated by European Medicines Agency

ADIL : 1.61 (unch)
Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell''

CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADILW : 0.20 (-31.03%)
ADIL : 1.61 (unch)
Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization

Adial Reaffirms on Track to Commence Phase 3 Trial in Q3 2019

ADIL : 1.61 (unch)
Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder

CHARLOTTESVILLE, VA / ACCESSWIRE / May 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today...

ADIL : 1.61 (unch)
Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City

CHARLOTTESVILLE, VA / ACCESSWIRE / April 30, 2019 / (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced William Stilley,...

ADIL : 1.61 (unch)
Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate

World-renowned addiction doctor talks about combating alcohol and opioid addiction during National Alcohol Awareness Month

ADIL : 1.61 (unch)
Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy

Adial to Advance Corporate Partnerships; Licensing and M&A Opportunities

ADIL : 1.61 (unch)
AVCO : 2.30 (-0.43%)
Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award

Lecture to focus on pharmacogenic treatment personalization for alcohol use disorder

ADIL : 1.61 (unch)
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.

CHARLOTTESVILLE, VA / ACCESSWIRE / April 3, 2019 / (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole...

ADIL : 1.61 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADIL with:

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

2nd Resistance Point 1.82
1st Resistance Point 1.71
Last Price 1.61
1st Support Level 1.54
2nd Support Level 1.47

See More

52-Week High 9.44
Fibonacci 61.8% 6.26
Fibonacci 50% 5.27
Fibonacci 38.2% 4.29
Last Price 1.61
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar